bioRxiv · 10.1101/2023.07.07.548156
A conserved antigen induces respiratory Th17-mediated serotype-independent protection against pneumococcal superinfection
Abstract
Several vaccines targeting bacterial pathogens show reduced efficacy in the context of intercurrent viral infection indicating a new vaccinology approach is required to protect against such superinfections. To find antigens for the human pathogen Streptococcus pneumoniae that are effective following influenza infection, we performed CRISPRi-seq in a murine model of superinfection and identified the highly conserved lafB gene as virulence factor. We show that LafB is a membrane-associated, intracellular protein that catalyzes the formation of galactosyl-glucosyl-diacylglycerol, a glycolipid we show is important for cell wall homeostasis. Respiratory vaccination with recombinant LafB, in contrast to subcutaneous vaccination, was highly protective against all serotypes in a murine model. In contrast to standard pneumococcal capsule-based conjugate vaccines, protection did not require LafB-specific antibodies but was dependent on airway CD4+ T helper 17 cells. Healthy human individuals can elicit LafB-specific immune responses, suggesting its merit as a universal pneumococcal vaccine antigen that remains effective following influenza infection. One-Sentence SummaryDiscovery of a universal pneumococcal vaccine protective during superinfection.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Liu, X., Van Maele, L., Matarazzo, L., Soulard, D., Alves Duarte da Silva, V., de Bakker, V., Denereaz, J., Bock, F. P., Taschner, M., Gruber, S., Nizet, V., Sirard, J.-C., Veening, J.-W.. 2023-07-07. A conserved antigen induces respiratory Th17-mediated serotype-independent protection against pneumococcal superinfection. https://doi.org/10.1101/2023.07.07.548156
Cite the original work for its findings. Save a collection to share your selection of sources.